Brief: Biocartis And Apis Assay Technologies Sign Collaboration To Develop Breast Cancer Subtyping Test
04/04/2023 06:07
April 4 (Reuters) - Biocartis Group Nv BCART.BR :
* PRESS RELEASE BIOCARTIS GROUP NV: BIOCARTIS AND APIS ASSAY
TECHNOLOGIES SIGN COLLABORATION TO DEVELOP AND COMMERCIALISE A
BREAST CANCER SUBTYPING TEST ON THE IDYLLA™ PLATFORM
* BIOCARTIS AND APIS ASSAY TECHNOLOGIES SIGN COLLABORATION
TO
DEVELOP AND COMMERCIALISE A BREAST CANCER SUBTYPING TEST ON
IDYLLA™ PLATFORM
Source text for Eikon: ID:nGNEb9fXR3
Further company coverage: BCART.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biocartis NV
See all newsBrief: Biocartis Group NV Appoints Randy Polonsky As Chief Financial Officer
Brief: Biocartis Appoints New Chief Business Officer, VP Global Marketing
Brief: Biocartis And Merck To Collaborate
Brief: Biocartis's Secured Creditors Enforced Their Security Over Subsidiaries Shares
Brief: Biocartis Announces Expansion Of Its Collaboration With Apis Assay Technologies